At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
Hashem B. El-Serag, MD, MPH
Advertisement
Articles by Hashem B. El-Serag, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
5